Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 6;40:246. doi: 10.1186/s13046-021-02047-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Tumor microenvironment phenotyping by flow cytometry and immunohistochemistry of p16⁺ and p16⁻ HNSCC. A Scatterplot depicting the percentage number of positive cells stained with the appropriate monoclonal antibodies followed by flow cytometric analysis and measuring 50,000 events in a live gate. Data analysis was performed using BD FACSuite software. HNSCC cases were separated according to the p16 status (i.e. p16⁺ of p16⁻). The number of tumor-infiltrating macrophages (CD14⁺CD163⁺ and CD14⁺CD204⁺) correlated with engraftment success. **p < 0.01 p16⁺ tumors vs. p16⁻ tumors; Mann Whitney U test. B Representative images showing PD-L1⁺ tumor and immune cells as well as infiltrating CD8⁺ cells in primary tumors. Tumor resection specimens were stained with the appropriate antibodies as stated in material & methods. The combined positive score (CPS) was calculated considering PD-L1 positivity in tumor and tumor-infiltrating immune cells. Additional information on engraftment success is given in the lower part (PDX – patient derived xenograft)